/Combination Therapies With Anti-cd38 Antibodies And Parp Or Adenosine Receptor Inhibitors
Abstract

This invention relates to a methods and compositions for treating a disease by administering a combination therapy comprising an anti-CD38 antibody and a poly ADP ribose polymerase inhibitor (PARPi); an anti-CD38 antibody and an adenosine receptor antagonist; or an anti-CD38 antibody, a PARPi and an adenosine receptor antagonist, to a subject (e.g., a human patient) in need thereof.

Full Text

What is claimed is:

This invention relates to a methods and compositions for treating a disease by administering a combination therapy comprising an anti-CD38 antibody and a poly ADP ribose polymerase inhibitor (PARPi); an anti-CD38 antibody and an adenosine receptor antagonist; or an anti-CD38 antibody, a PARPi and an adenosine receptor antagonist, to a subject (e.g., a human patient) in need thereof.
Timeline
Filed
06/03/2026
Published
09/17/2026
Granted
Not Available
IPC Codes(6)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61K 31/4439:containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K 31/465)
A61K 31/502:ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine